Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASTRO 2022 | Future role of PSMA PET/CT for prostate cancer management

Wesley Armstrong • 28 Oct 2022
ASTRO 2022
Genitourinary Cancer Prostate Cancer

Wesley Armstrong, BS, UCLA, Los Angeles, CA, discusses the potential implementation of PSMA PET/CT for informing treatment management for patients with prostate cancer. Further data is expected on survival outcomes from a Phase III trial (NCT03582774) investigating the impact of PSMA PET/CT on salvage radiotherapy planning for prostate cancer patients. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wesley Armstrong

3:13
Phase III trial of the impact of PSMA PET/CT in salvage radiotherapy management
Wesley Armstrong • 28 Oct 2022
2:39
How to get the most out of attending conferences as a medical student
Wesley Armstrong • 28 Oct 2022
2:08
Highlights of ASTRO 2022 for prostate cancer
Wesley Armstrong • 28 Oct 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals